Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs

BMC Veterinary Research

Volumn 8, Issue , 2012, Pages

  Sherger, Matthew ^a   Kisseberth, William ^a   London, Cheryl ^a   Olivo Marston, Susan ^a   Papenfuss, Tracey L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; Immunosuppression; Myeloid derived suppressor cells

Indexed keywords

CANIS FAMILIARIS; MUS;

CD11B ANTIGEN; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BONE MARROW CELL; DOG; DOG DISEASE; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; NEOPLASM; NONPARAMETRIC TEST; PATHOLOGY; PROSPECTIVE STUDY;

ANIMALS; ANTIGENS, CD11B; DOG DISEASES; DOGS; FLOW CYTOMETRY; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; MYELOID CELLS; NEOPLASMS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84868232767     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-8-209     Document Type: Article

References (36)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(3):162-174. 10.1038/nri2506, 2828349, 19197294.
2. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010, 40(11):2969-2975. 10.1002/eji.201040895, 3277452, 21061430.
3. Medzhitov R, et al. Highlights of 10 years of immunology in Nature Reviews Immunology. Nat Rev Immunol 2011, 11(10):693-702. 10.1038/nri3063, 21941295.
4. Krystal G, et al. Re: the terminology issue for myeloid-derived suppressor cells. Cancer Res 2007, 67(8):3986. 10.1158/0008-5472.CAN-07-0211, 17440115.
5. Kirchner H, et al. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med 1974, 139(6):1473-1487. 10.1084/jem.139.6.1473, 2139691, 4598016.
6. Gabrilovich DI, et al. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996, 170(1):111-119. 10.1006/cimm.1996.0140, 8665591.
7. Diaz-Montero CM, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58(1):49-59. 10.1007/s00262-008-0523-4, 3401888, 18446337.
8. Ko JS, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009, 15(6):2148-2157. 10.1158/1078-0432.CCR-08-1332, 19276286.
9. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009, 24(3):106-112. 10.1053/j.tcam.2009.02.002, 19732728.
10. Ugel S, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009, 9(4):470-481. 10.1016/j.coph.2009.06.014, 19616475.
11. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006, 16(1):53-65. 10.1016/j.semcancer.2005.07.005, 16168663.
12. Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25(8):911-920. 10.1038/nbt1323, 17664940.
13. Fujita M, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011, 71(7):2664-2674. 10.1158/0008-5472.CAN-10-3055, 3075086, 21324923.
14. Bunt SK, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67(20):10019-10026. 10.1158/0008-5472.CAN-07-2354, 17942936.
15. Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009, 69(13):5514-5521. 10.1158/0008-5472.CAN-08-4625, 2706931, 19549903.
16. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007, 13(18 Pt 1):5243-5248.
17. Pan PY, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010, 70(1):99-108. 10.1158/0008-5472.CAN-09-1882, 2805053, 19996287.
18. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010, 59(10):1593-1600. 10.1007/s00262-010-0855-8, 20414655.
19. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182(8):4499-4506. 10.4049/jimmunol.0802740, 2810498, 19342621.
20. Bergman PJ, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24(21):4582-4585. 10.1016/j.vaccine.2005.08.027, 16188351.
21. Goulart MR, Pluhar GE, Ohlfest JR. Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One 2012, 7(3):e33274. 10.1371/journal.pone.0033274, 3302813, 22428007.
22. Mitchell L, Thamm DH, Biller BJ. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 2012, 26(2):355-362. 10.1111/j.1939-1676.2011.00883.x, 22303814.
23. Kobayashi T, et al. Canine hair-follicle keratinocytes enriched with bulge cells have the highly proliferative characteristic of stem cells. Vet Dermatol 2009, 20(5-6):338-346.
24. Mazzone A, et al. Correlation between CD11b/CD18 and increase of aggregability of granulocytes in coronary artery disease. Inflammation 1992, 16(4):315-323. 10.1007/BF00917624, 1526663.
25. Lin TY, Rush LJ, London CA. Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol 2006, 113(1-2):37-52.
26. Pinet F, et al. Morphology, homogeneity and functionality of human monocytes-derived macrophages. Cell Mol Biol (Noisy-le-grand) 2003, 49(6):899-905.
27. Schuberth HJ, et al. Reactivity of cross-reacting monoclonal antibodies with canine leukocytes, platelets and erythrocytes. Vet Immunol Immunopathol 2007, 119(1-2):47-55.
28. Rebuck N, Finn A. Polymorphonuclear granulocyte expression of CD11a/CD18, CD11b/CD18 and L-selectin in normal individuals. FEMS Immunol Med Microbiol 1994, 8(3):189-195. 10.1111/j.1574-695X.1994.tb00442.x, 7516231.
29. Dosogne H, et al. Increased surface expression of CD11b receptors on polymorphonuclear leukocytes is not sufficient to sustain phagocytosis during Escherichia coli mastitis in early postpartum dairy cows. Vet Immunol Immunopathol 1997, 60(1-2):47-59.
30. Chang HH, et al. Multistable and multistep dynamics in neutrophil differentiation. BMC Cell Biol 2006, 7:11. 10.1186/1471-2121-7-11, 1409771, 16507101.
31. Furuhashi K, et al. Mouse lung CD103+ and CD11bhigh dendritic cells preferentially induce distinct CD4+ T-cell responses. Am J Respir Cell Mol Biol 2012, 46(2):165-172. 10.1165/rcmb.2011-0070OC, 21908266.
32. Porembka MR, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 2012,
33. Zhao F, et al. S100A9 a new marker for monocytic human myeloid derived suppressor cells. Immunology 2012,
34. Ryzhov S, et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 2011, 187(11):6120-6129. 10.4049/jimmunol.1101225, 3221925, 22039302.
35. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011, 11(7):802-807. 10.1016/j.intimp.2011.01.003, 3478130, 21237299.
36. Raychaudhuri B, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011, 13(6):591-599. 10.1093/neuonc/nor042, 3107102, 21636707.